Novel CDK2 Inhibitor INCB123667 Shows Promise in Ovarian Cancer
The CDK2 inhibitor INCB123667 showed positive efficacy and safety signals in platinum-resistant/refractory ovarian cancer.
The CDK2 inhibitor INCB123667 showed positive efficacy and safety signals in platinum-resistant/refractory ovarian cancer.
Results from a Q-TWiST analysis of the LITESPARK-005 trial showed a trend favoring belzutifan over everolimus for patients with clear cell RCC.
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
No single method of sun protection can safeguard you perfectly. A complete strategy is the best way to protect yourself against skin cancer.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Volunteers are important members of the Huntsman Cancer Institute (HCI) team. Volunteer opportinities include comforting patients and their families, working with various HCI services, assisting…
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
In this issue of Blood, Papadopoulos et al delineate myeloproliferative leukemia virus oncogene (MPL)-dependent and -independent phenotypes of JAK2V617F+ m